ArticleTurkish journal of medical sciences2025
The impact of tizanidine, thiocolchicoside, and cyclobenzaprine on vascular function in ovariectomized rats.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Menopause is associated with increased vascular risk. This study investigated the effects of 3 centrally acting muscle relaxants-tizanidine (TZ), thiocolchicoside (TCC), and cyclobenzaprine (CBZ)-on vascular reactivity in ovariectomized (OVX) rats as a model of menopause. Materials and methods: Body weight, blood glucose, blood pressure, and heart rate were recorded, and the rats underwent oophorectomy surgery. Eight weeks after the operation, the rats were divided into 5 groups: sham operated rats, OVX rats, OVX rats treated with TZ (OVX + TZ), OVX rats treated with TCC (OVX + TCC), and OVX rats treated with CBZ (OVX + CBZ). All drug treatments were at a dosage of 2 mg/kg/day for 2 weeks. Isolated rat aortas were suspended in a tissue chamber. Vascular reactivity was assessed using increasing concentrations of phenylephrine, acetylcholine, and sodium nitroprusside, as well as potassium chloride at a concentration of 40 mM. Results: Body weight, phenylephrine sensitivity, and potassium chloride responses significantly increased with OVX. TZ and CBZ decreased body weight gain and ameliorated receptor-dependent contractile sensitivity. TZ and CBZ had calcium antagonistic effects on vascular smooth muscle. TZ deteriorated endothelial function. Conclusion: TZ cannot be considered a safe medication for patients with endothelial dysfunction. In high doses and for longer periods, TCC and CBZ might also have deleterious effects on vascular reactivity. These findings are noteworthy from the perspective of rational drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.